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ABSTRACT
OBJECTIVE: To evaluate the immunogenicity and safety of a novel hepatitis 
B vaccine, after increasing antigen concentration to 25 μg, in comparison to 
the reference vaccine.
METHODS: Single-blinded randomized trial comparing VrHB-IB (Instituto 
Butantan) and the reference vaccine (Engerix B®, Glaxo Smith Kline). 
Volunteers aged 31 to 40 years were randomized to either experimental (n=216) 
or control (n=203) groups, and were given three doses of vaccine. The fi rst 
dose was administered upon recruitment, and the second and third doses 30 
and 180 days later, respectively, between 2004 and 2005. Blood samples were 
collected for analysis before randomization and after the second and third 
doses. Active search for adverse effects was perforned in the fi rst fi ve days 
after vaccination. Differences were evaluated using chi-square and Fisher’s 
exact tests, with a 5% signifi cance level.
RESULTS: No severe adverse effects were observed. Seroprotection was 
confi rmed in 98.6% (213/216) of volunteers in the experimental group and 
95.6% (194/203) of those in the control group. Geometric mean titers were 
12,557 and 11,673, respectively.
CONCLUSIONS: The Brazilian vaccine was considered to be equivalent to 
the reference vaccine and its use is recommended for adults.
DESCRIPTORS: Hepatitis B Vaccines. Effi cacy. Hepatitis B, prevention 
& control. Controlled Clinical Trial.
2 Immunogenicity of a hepatitis B vaccine Moraes JC et al
Hepatitis B is still a global public health problem. The 
World Health Organization estimates that roughly 2 
billion people have been infected by the hepatitis B 
virus, of which 350 million are chronically infected.a 
Chronically infected patients are at high risk of 
death from hepatic cirrhosis and liver cancer. Annual 
hepatitis B-associated mortality is estimated at 600 
thousand deaths.b
In Brazil, areas of high and moderate hepatitis B 
endemicity include the Western Amazon, Western 
and Southern Paraná, Western Santa Catarina, the 
Jequitinhonha valley in the state of Minas Gerais, 
and certain areas in the state of Mato Grosso. Low 
endemicity areas include the remainder of the Brazlian 
South and Center-West, as well as the Northeast and 
Southeast. Recent studies have shown an impressive 
decline in prevalence of chronic hepatitis B infection in 
the Western Amazon, possibly as a result of vaccination 
strategies. Preliminary results of the National Survey of 
Viral Hepatitides have provided estimated prevalences 
of 0.11% and 0.5% among 10- to 19-year-olds and 20- 
to 69-year-olds, respectively, in the Northeast Region 
and of 0.17% and 0.75% in these same age groups in 
the Center-West Region.1,4,5,16
Despite such reductions in prevalence, however, hepa-
titis B remains an important public health concern in 
Brazil.
In the past three decades, several advancements have 
been made in the development of vaccines protective 
against hepatitis B, from the use of 22 nm non-infectious 
viral particles purifi ed from the plasma of asymptomatic 
HBV carriers to the large-scale production of vaccines 
using recombinant DNA technology. Much has been 
published on the safety, immunization schemes, and 
effi cacy of this vaccine, and current formulations are 
safe, immunogenic, and capable of preventing the large 
majority of cases of infection, thus drastically reducing 
HBV-related mortality.6
The effi cacy of the recombinant HBV vaccine was 
initially demonstrated in 1980, in the classical study by 
Szmuness et al,14 which showed reduced incidence of 
HBV infection in a population of men who had sex with 
men. The hepatitis B vaccine is highly immunogenic 
and protective against HBV infection. A response is 
considered to be protective when the vaccine elicits the 
formation of antibodies to HBsAg (anti-HBs) at a level 
equal to or greater than 10 mUI/ml as determined by 
immunoenzymatic assay. A complete series of three or 
four doses of hepatitis B vaccine is capable of eliciting 
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a World Health Organization. Hepatitis B. Geneva; 2008[cited 2008 Oct 28]. (Fact sheet, 204). Available from: www.who.int/mediacentre/
factsheets/fs204/en
b World Health Organization. Hepatitis B. Geneva; 2008[cited 2009 May 20]. Available from: www.who.int/immunization_monitoring/
diseases/hepatitis/en
a protective response in over 90% of healthy adults and 
over 95% of healthy children and adolescents. Though 
vaccination schemes may vary, the usual recommenda-
tion consists of either three doses administered at zero, 
one, and six months, or four doses administered at zero, 
one, two, and 12 months. Vaccination induces antibody 
titers in the order of 1,000 to 3,000 mUI/ml in adults 
and higher than 5,000 mUI/ml in children.15
The initial response to vaccination decreases with incre-
asing age. Among healthy children, adolescents, and 
young adults (20-39 years), protective immunization is 
generally higher than 90%, falling to 70% among adults 
aged 50-59 years and to 50% among those 60 years or 
older. Other factors infl uencing the immunogenicity of 
the vaccine include smoking, obesity, and immunosup-
pressive diseases, including diabetes mellitus, corticos-
teroid treatment, chronic renal insuffi ciency, and HIV 
infection.8,12 Still, a proportion of healthy individuals, 
ranging from 2.5% to 5%, do not respond satisfactorily 
to HBV vaccination. Such individuals are considered to 
be unresponsive to the hepatitis B vaccine.3,11
The Food and Drug Administration recognized the 
safety of the hepatitis B vaccine based on an evaluation 
of 12 million doses of vaccine administered to infants. 
Side-effects are similar to those of other licensed 
vaccines. Pain and hyperemia at the injection site are 
the most frequent adverse effects (15%-20%), and are 
likely to be caused by the vaccine’s adjuvant, aluminum 
hydroxide.10,14 Approximately 15% of vaccinated indi-
viduals experience one or more mild and self-limiting 
systemic symptoms, such as cephalea, fever, and/or 
fatigue, usually 24 to 28 hours after vaccination.13
The Instituto Butantan (IB) in São Paulo began the 
production of a hepatitis B vaccine using recombinant 
DNA technology (VrHB-IB). This vaccine was initially 
formulated using 20 μg of recombinant HBsAg, with 
aluminum hydroxide as an adjuvant. Preliminary studies 
in healthy adult volunteers, using 20 μg of antigen per 
dose in a zero, one, and six month immunization 
scheme, showed that the IB vaccine did not induce 
signifi cant adverse effects and led to seroconversion 
in 95.3% of subjects.2 It was later found that the IB 
formulation was not as effective in eliciting an immune 
response in subjects older than 45 years, with 70% sero-
conversion among these subjects in comparison with 
100% in the 18-25 years age group. Moreover, given 
the differences in geometric mean antibody titer after 
vaccination between the 20 μg dose of the test vaccine 
and the control vaccine, the authors suggested the need 
for increasing antigen concentration in the vaccine.7
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As a complement to previous studies, the Brazilian 
Ministry of Health sponsored a multicenter trial aimed 
at evaluating the immunogenicity and safety of the IB 
vaccine in different age groups. This trial used Engerix 
B®, produced by Glaxo Smith Kline, as a reference 
HBV vaccine. This vaccine is obtained using the same 
genetic engineering technology as the IB vaccine, and 
is acknowledgedly safe and highly immunogenic.
The multicenter trial concluded that the IB vaccine was 
safe and elicited a good immune response in children, 
adolescents, and young adults. However, the response 
among adults aged 31 to 40 years was unsatisfac-
tory, with 79.9% of subjects becoming seroproteced, 
compared to 92.5% using Engerix B®.9
It was therefore concluded that the IB vaccine should 
be improved before it could safely be used in adults. 
Instituto Butantan thus reformulated the vaccine as an 
attempt to increase its immunogenicity. HBs antigen 
concentration was increased from 20 to 25 μg/dose, 
which yielded an eletrophoretic profi le similar to that 
of Engerix B®.
The aim of the present study was to analyze the immu-
nogenicity of the reformulated VrHB-IB in healthy 
adults, in comparison with the reference vaccine.
METHODS
We carried out a single-blinded, controlled, randomized 
trial. Volunteers, aged 31 to 40 years, were recruited 
from among the personnel of the City of Sao Paulo 
Metropolitan Police, in the municipality of São Paulo, 
Southeastern Brazil. Subjects were divided into two 
groups: the experimental group received VrHB-IB 
in the 25 μg/dose formulation, and the control group 
received the vaccine considered as standard, Engerix 
B® at 20 μg/ml, from Glaxo Smith Kline. Each parti-
cipant received three doses of one of the vaccines, at 
days zero, 30 or later, and 180 or later. Blood samples 
were collected before the fi rst and third doses, and 30 
days after the third dose. Beginning on the fi fth day 
after each dose, subjects were contacted to collect 
information on adverse effects. Fieldwork was carried 
out between the second semester of 2004 and the fi rst 
semester of 2005.
VrHB-IB was provided by the Brazilian Ministry of 
Health’s National Immunization Program, and Engerix 
B® was purchased directly from the manufacturer. All 
doses administered came from the same lot of each of 
the vaccines.
Inclusion criteria were as follows: age 31 to 40 years, 
agreeing to participate in the study by signing a 
term of free informed consent, absence of any sero-
logical marker of hepatitis B, and nonreagent HIV 
serology. Exclusion criteria included presence of 
immunosuppressive diseases or renal insuffi ciently 
and use of corticosteroids. In addition to these criteria, 
we also excluded from follow-up any volunteers who 
received other doses of hepatitis B vaccine in addition 
to those provided by the trial; missed any of the later 
vaccine doses or blood sample collections; or expressed 
the will to leave the trial at any moment.
The present study is characterized as a vaccine non-
inferiority trial,18 the goal of which is to demonstrate 
that the proportion of subjects with the desired immu-
nogenic response to the novel vaccine is not inferior 
to that of the control group beyond a preestablished 
non-inferiority threshold. For sample size calculation, 
we used the following parameters: maximum difference 
in seroprotection between the two vaccines of 0.075; 
proportion of seroprotection in the control vaccine of 
0.93; proportion of seroprotection in the experimental 
vaccine of 0.95; 0.95 confi dence level; 90% statistical 
power; 20% losses to follow-up; and one-tailed statis-
tical analysis. Using PASS statistical software to test 
equivalence of proportions, we determined the neces-
sary sample size at 260 subjects per group.
The population of policemen within the age group of 
interest was estimated at approximately 3,000. We 
included 564 subjects in the sample (18.8% of the total): 
283 were allocated in the experimental group and 281 
in the control group. There were no differences between 
the groups in terms of sex, age, and other baseline 
characteristics. Of this total, 145 volunteers were lost 
to follow-up in the course of the study. Losses were 
distributed equally between the two groups. The major 
reason for loss was voluntary drop out (63.4%).
The analysis was per-protocol, including only those 
subjects that completed all steps of the trial: pre-vaccine 
serology; administration of three doses of vaccines; 
interval between the two fi rst doses of 28 days or 
longer; interval between the second and third doses of 
at least 120 days; interval between the third dose and 
the fi nal blood sample of 28 to 100 days; quantitative 
fi nal dosage of anti-HBs.
We adopted the necessary procedures to ensure blin-
ding, so that neither subjects nor laboratory personnel 
who determined anti-HBs titers had access to grouping 
information. Subject entries were numbered, and the 
vaccine to be used was randomly assigned. The group 
status was known by the study coordinator and fi el-
dwork team, since vaccine presentations were different 
(single dose in the case of EngerixB® and 5 ml vials in 
the case of VrHB-IB). Adverse effect evaluation charts 
did not contain information on the vaccine used.
Samples were collected, centrifuged, and aliquoted 
by the Central Laboratory of the Santa Casa de 
Misericórdia de São Paulo (LC-SCMSP), and those 
from the second and third samples were sent to the 
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Instituto Oswaldo Cruz/ Fundação Oswaldo Cruz 
(IOC/FIOCRUZ) for serological evaluation. The fi rst 
sample was analyzed by the LC-SCMSP immediately 
after collection for presence of hepatitis B markers 
(HBsAg, total anti-HBc, anti-HBc IgM, and an-HBs) 
and HIV 1 and 2. Antibody titers were determined by 
microparticle enzyme immunoassay (MEIA) using 
AXSYN automated equipment (Abbot), strictly as 
recommended by the manufacturer. Samples reactive 
or inconclusive at the baseline were retested.
Quantitative dosage of anti-HBs (in international miliu-
nits of anti-HBs per milliliter – mUI/ml) was performed 
on the second and third samples using a commer-
cially available immunoenzymatic assay (ACCESS® 
AbHBsII, Beckman Coulter). This system is fully 
automatic, ensuring the reproducibility of the obtained 
results. For quality control purposes, 10% of samples 
were retested by an independent laboratory (Instituto 
Evandro Chagas, Ministry of Health, Belém – PA).
Seroprotection was defi ned as a titer equal to or greater 
than 10 mUI/ml. We calculated arithmetic mean, 
median, and geometric mean titers at each timepoint. 
Titers were classifi ed into the following categories: < 
10 (negative), 10 – 100 (weakly positive), and > 100 
(strongly positive).
After each procedure, all data collection instruments 
were rechecked in search of empty fi elds and inconsis-
tencies. When necessary, we contacted subjects in order 
to complement the available information.
Following data entry into the database, we proceeded 
to exploratory analysis, which consisted of calculating 
distribution and central tendency/dispersion to verify 
the success of randomization both in the original cohort 
and in the group of subjects that completed the protocol. 
For immunogenicity evaluation we considered two 
variables: “anti-HBs titer 3” (referent to the third blood 
sample) and its derivative, “seroprotection.” Individuals 
presenting anti-HBs greater or equal to 10 UI/ml were 
considered seroprotected.
The proportion of adverse effects for each vaccine 
was compared, and differences were evaluated by chi-
squared and Fisher’s exact tests, adopting a signifi cance 
level of 5%.
We carried out an analysis of the magnitude of losses 
and whether they differed between groups, which could 
bias the analysis.
We adopted as a criterion for signifi cance, i.e., as a 
probability of the difference being signifi cant, a p-value 
below 0.05.
The study protocol was approved by the Research 
Ethics Committee of the Faculdade de Ciências 
Médicas of the Santa Casa de São Paulo. The study was 
planned and developed independently from the manu-
facturers of the vaccines involved. The Term of Free 
Informed Consent, containing a general description of 
the study, its objectives, procedures, risks and benefi ts 
to the participant, guarantees in the case of occurrence 
of adverse effects, and the names of those responsible 
for the project was read and discussed jointly between 
a member of the team and the volunteer candidate.
RESULTS
Table 1 presents the frequency of adverse reactions 
reported by participants after each dose. The frequency 
of reported adverse reactions decreased from each 
dose to the next in both groups. Analyzing each dose 
separately, there was no signifi cant difference in the 
frequency of adverse reactions to each vaccine, with 
the exception of the third dose, after which the inci-
dence of adverse reactions was higher among subjects 
receiving VrHB-IB (χ² = 4.16; p< 0.05). Most common 
complaints following immunization were pain at the 
site of injection, sleepiness, and headaches. No severe 
side effects were reported.
Table 1. Frequency distribution of adverse effects reported after each vaccine dose, according to type of vaccine. Municipality 
of São Paulo, Southeastern Brazil, 2004-2005.
Vaccine
1st dose 2nd dose 3rd dose
Total With adverse effect % Total With adverse effect % Total With adverse effect %
VrHB-IB 283 80 28.3 242 47 19.4 225 40 17.8ª
Engerix® 281 87 31.0 226 37 16.4 210 22 10.5ª
Total 564 167 29.6 468 84 17.9 435 62 14.2
ª χ2 = 4.16, p = 0.04
Table 2. Distribution of seroprotection according to vaccine 
type. Municipality of São Paulo, Southeastern Brazil, 2004-
2005.
Vaccine
Negative Positive Total
n % n % n %
VrHB-IB 3 1.4 213 98.6 216 100.0
Engerix® 9 4.4 194 95.6 203 100.0
Total 12 2.9 407 97.1 419 100.0
χ2 = 2.48, p = 0.11
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Seroprotection was assessed in the samples collected 
one month after the third dose of vaccine. Table 2 
shows that only 12 of the 419 samples tested were 
negative, i.e., only 12 subjects (2.9% of the total) were 
not seroprotected after having received three doses of 
the vaccine. This proportion was 1.4% and 4.4% for 
VrHB-IB and Engerix B®, respectively. The difference 
between the vaccines was not signifi cant. The geometric 
mean titers for each vaccine were 12,577 and 11,673, 
respectively, for the IB vaccine and for Engerix B®. 
The Kruskal-Wallis statistic for this comparison was 
5.04, i.e., mean antibody titers obtained with the the IB 
vaccine were signifi cantly higher than those obtained 
using Engerix B®.
Table 3 shows that 90.2% of vaccinated subjects were 
strongly reactive. This included 95.4% of subjects in 
the IB vaccine group and 84.7% of those in the Engerix 
B® group, a statistically signifi cant difference (χ² = 
13.4; p <0.01).
For quality control purposes, the anti-HBs titers of 61 
randomly selected samples were retested by a diffe-
rent laboratory. The intraclass correlation coeffi cient 
between the two tests was 0.973 (95%CI: 0.955;0.984), 
evidence of a strong correlation.
DISCUSSION
The hepatitis B vaccine manufactured by Instituto 
Butantan showed a similar safety profi le to that of 
the reference vaccine. Most adverse events reported 
consisted of localized reactions and non-specifi c symp-
toms. As reported for other recombinant hepatitis B 
vaccines, we detected no severe adverse effects.18
In a prior trial17 in volunteers of the same age group, a 
signifi cant difference was detected in the immunogeni-
city of the IB vaccine when compared to the reference, 
exceeding the previously established limit of 5%. In 
the group that received the IB vaccine (20 μg), 79.8% 
of subjects were effectively immunized, vs. 92.4% of 
those receiving the reference vaccine.17 In the present 
trial, using the 25 μg dose, the immunogenicity of the 
IB vaccine was virtually identical to that of the stan-
dard vaccine, with high antibody titers being induced 
in the majority of subjects (95.4% of titers higher than 
100mUI/ml).
A range of factors may infl uence the results of trials of 
recombinant hepatitis B vaccines, such as, for instance, 
differences in formulation and manufacturing, vaccina-
tion schedule, age at vaccination, site of vaccine admi-
nistration, the laboratory test used to determine results, 
and differences between study populations, among 
others. Thus, comparisons between different studies 
should be undertaken with caution. On the other hand, 
proper randomization of volunteers into experimental 
and control groups ensures that factors potentially 
associated with the results are uniformly distributed. In 
the present study, we detected no difference between 
groups regarding baseline characteristics, showing that 
randomization was successful.
The proportion of losses was somewhat higher than 
expected. Considering that they were distributed 
equally between the two groups, and also given the 
robustness of our results, we consider that such a 
proportion of losses would be unlikely to infl uence the 
results of the trial.
Both vaccines achieved strong seroconversion (above 
100 U of anti-HBs per ml) after the third dose, with 
high mean titers. The results obtained show that the two 
vaccines are equivalent in terms of immunogenicity and 
reactogenicity among the 31-40-year-old population, 
and therefore that the Instituto Butantan vaccine can 
be widely used for the control of such an important 
endemic disease in Brazil.
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